Tumor Genome Profiling Technology and Genomics Research Services from Mount Sinai Services: Offering of Personalis
Reporter: Aviva Lev-Ari, PhD, RN
Personalis, Mount Sinai Services to Offer Tumor Genome Profiling Technology
Personalis announced today that it has signed a letter of intent to offer its next-generation tumor sequencing and interpretation technology in Canada through a collaboration with Toronto-based lab and research services firm Mount Sinai Services.
Under the terms of the deal, the two will
- create a framework to offer Personalis’ Accuracy and Content Enhanced (ACE) technology for
- clinical diagnostic and
- research tumor molecular profile sequencing and analysis, as well as
- immuno-oncology sequencing clinical trials, to customers throughout Canada.
Personalis currently sells the ACE CancerPlus test for solid tumors, which provides a report on 181 clinically relevant genes to provide tumor genomic profile data that can help guide therapy and research. The company also offers ACE ImmunoID assays for the analysis of tumor mutation burden and neoantigen identification.
RELATED ARTICLES
Leave a Reply